An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy - RENEW

BioCryst Pharmaceuticals Inc0 个研究点目标入组 42 人开始时间: 2022年4月8日最近更新: 2023年1月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: BioCryst Pharmaceuticals Inc
入组人数: 42

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Willing and able to provide written informed consent
•2.Male or non-pregnant, non-lactating female subjects = 18 years of age
•3.Body weight = 40 kg.
•4.Primary diagnosis of C3G, IgAN, or PMN with evidence of disease
•activity as, confirmed by central pathology review of digital images and
•pathology reports of renal biopsy samples
•5.For subjects with C3G only, documentation of duration of illness of at least 90 days by either a prior biopsy collected = 90 days prior to screening confirming a diagnosis of C3G OR a clinical diagnosis of C3G with at least one documented proteinuria assessment = 90 days prior to initial screening visit.
•6.For subjects with C3G only, proteinuria defined as = 1 g of urinary protein per 24 hours at screening that has not shown a = 25% decrease from the most recent documented proteinuria assessment, which was collected = 30 days prior to and = 180 days of initial screening visit.
•7.For subjects with IgAN only, proteinuria defined as 1 g to = 4 g of urinary protein per 24 hours at screening that has not shown a = 25% decrease from the most recent documented proteinuria assessment, which was collected = 30 days prior to and = 180 days of initial screening visit.
•8.For subjects with PMN only, an anti-phospholipase A2 receptor antibody (aPLA2Rab) Immunoglobulin G (IgG) titer of = 150 U/mL and 3.5 g to =11 g of urinary protein per 24 hours at screening that has not shown a = 25% decrease from the most recent documented proteinuria assessment, which was collected = 30 days prior to and = 180 days of initial screening visit.
•9.An eGFR = 50 mL/min/1.73 m2 (or = 30 mL/min/1.73 m2 after DMC recommendation)
•10.Resting supine vital signs within the following ranges:
•Systolic blood pressure, 80 to 150 mm Hg, inclusive, for adults
•Systolic blood pressure below the 90th percentile, for adolescents per Section 12.10.1
•Diastolic blood pressure = 90 mm Hg
•11.Treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1
•12. Contraception requirements - WOCBP and female partners of male subjects to use highly effective contraception methods
•13.Documentation of current vaccination against N. meningitidis Types A, C, W and Y, and S. pneumoniae vaccine, or must be vaccinated or willingness to start vaccination series at least 14 days prior to Day 1
•14.In the opinion of the investigator, the subject is expected to comply adequately with all required study procedures and restrictions for the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

排除标准

•1.Known congenital deficiency of C1s, C1r, C1q, C2, C4. Known variants in complement factor H, complement factor I, C3, and complement factor B or genomic rearrangements in the complement factor-H-related proteins are not exclusionary.
•2.Receiving hemodialysis or peritoneal dialysis or anticipated to receive dialysis during the duration of this study.
•3.History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation during the study.
•4.History of transfusion with blood or blood products, or plasmapheresis or plasma exchange, within 30 days prior to screening.
•5.Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition, including unstable angina, severe congestive heart failure, unexplained syncope, arrhythmia, and critical aortic stenosis.
•6.History of malignancy within 5 years prior to the screening visit, with the exception of adequately treated non-melanoma skin or superficial bladder cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor deemed by the investigator and medical monitor to be at low risk for recurrence.
•7.Any clinical or pathological evidence of monoclonal gammopathy of unclear or renal significance, lupus or other systemic autoimmune disease, or other conditions (eg, infection-associated disease or associated with another systemic disease, anti-phospholipid antibody syndrome with significant clinical disease, immune complex glomerulonephritis, immunoglobulin A [IgA] vasculitis with nephritis [Henoch-Schönlein purpura] or morphologic features of secondary membranous nephropathy). Presence of C3 or C5 nephritic factors (eg, autoantibodies directed at C3 or C5 convertase), in the absence of known infection or other systemic disease, are not exclusionary for this study.
•8.Treatment with azathioprine, canakinumab, cyclophosphamide,
•cyclosporine, eculizumab, everolimus, hydroxychloroquine, infliximab, sirolimus, ravulizumab, systemic corticosteroids(including budesonide), tacrolimus, or any other systemic immunosuppressive or immunomodulatory therapies (eg. complement inhibitors)within 90 days OR mycophenolate mofetil/mycophenolate soldium treatment within 60 days for anti-CD20 antibody therapies (eg, rituximab) within 180 days, prior to the screening visit.
•a.For subjects with C3G only, ongoing treatment with a stable dosing regimen of mycophenolate mofetil/mycophenolate sodium for at least 6 months prior to Day 1 Visit is allowed.
•9.Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1.
•10.Current participation in any other investigational drug study or participation in an investigational drug study within 30 days prior to the screening visit, or 5.5 half-lives of the investigational drug, whichever is longer.
•11.Any of the following at screening: Hb < 8.5 g/dL; WBC < 2.5 × 109/L; ANC < 1.0 × 109/L; platelet count < 90 × 109/L; ALT, AST, ALP or total bilirubin > 1.5 × ULN; serum albumin < 1.5 g/dL; or international normalized ratio (INR) > 1.4.
•a.Subjects with Grade 1 elevated bilirubin due to Gilbert’s syndrome are allowed to enroll
•12.Any laboratory parameter at screening that is clinically significant and would represent a safety concern.
•13.Clinically significant abnormal electrocardiogram (ECG) prior to dosing at

研究者

发起方

BioCryst Pharmaceuticals Inc

相似试验

进行中（未招募）

1 期

Evaluating oral BCX9930 in renal diseasescomplement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathyMedDRA version: 20.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 21.1Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10077827Term: C3 glomerulopathySystem Organ Class: 10038359 - Renal and urinary disorders

EUCTR2020-005855-19-ITBIOCRYST PHARMACEUTICALS INC.2

进行中（未招募）

1 期

EUCTR2020-005855-19-ESBioCryst Pharmaceuticals Inc42

进行中（未招募）

1 期

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 21.1Level: PTClassification code 10013916Term: DyskinesiaSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2019-001807-19-ITTEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC44

进行中（未招募）

1 期

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1Level: LLTClassification code 10068804Term: Athetoid cerebral palsySystem Organ Class: 100000004850

EUCTR2019-001807-19-GBTeva Branded Pharmaceutical Products R&D, Inc.185

进行中（未招募）

1 期

EUCTR2019-001807-19-PLTeva Branded Pharmaceutical Products R&D, Inc.185